Darob mite - Darob mite is in a group of drugs called beta-blockers. Beta-blockers affect the heart and circulation (blood flow through arteries and veins).
Darob mite is used to help keep the heart beating normally in people with certain heart rhythm disorders of the ventricles (the lower chambers of the heart that allow blood to flow out of the heart). Darob mite is used in people with ventricular tachycardia or ventricular fibrillation.
Another form of this medicine, called Darob mite AF, is used to treat heart rhythm disorders of the atrium (the upper chambers of the heart that allow blood to flow into the heart). Darob mite AF is used in people with atrial fibrillation or atrial flutter. Darob mite (Betapace and Sorine) is not used for the same conditions that Darob mite AF (Betapace AF) is used for.
Darob mite may also be used for other purposes not listed in this medication guide.
Darob mite is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, Darob mite inhibits the inward potassium ion channels of the heart. In so doing, Darob mite prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of Darob mite is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Darob mite does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.
Oral Supraventricular and ventricular arrhythmias
Adult: Initially, 80 mg daily as a single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg daily in 2 divided doses. Max: 640 mg daily.
Child: Neonates: Initially, 1 mg/kg bid, increased every 3-4 days, if necessary. Max: 4 mg/kg bid. 1 mth-12 yr: Initially, 1 mg/kg bid, increased as necessary every 2-3 days. Max: 4 mg/kg bid, not exceeding 80 mg bid. For refractory supraventricular tachycardia, Darob mite may be given with flecainide; <1 yr: 100-250 mg/m 2 daily of Darob mite and 40-150 mg/m 2 daily of flecainide. CrCl (ml/min) Dosage Recommendation 30-60 Halve the usual dose. 10-30 Quarter the usual dose. <10 Not recommended. Oral Life-threatening ventricular arrhythmias
Adult: 480-640 mg daily. CrCl (ml/min) Dosage Recommendation 30-60 Halve the usual dose. 10-30 Quarter the usual dose. <10 Not recommended. Intravenous Acute arrhythmias
Adult: 20-120 mg (0.5-1.5 mg/kg) given by inj over 10 min, may repeat every 6 hr if needed. To substitute for oral treatment, 0.2-0.5 mg/kg/hr infusion may be used. CrCl (ml/min) Dosage Recommendation 30-60 Halve the usual dose. 10-30 Quarter the usual dose. <10 Not recommended. Intravenous Programmed electrical stimulation (to test antiarrhythmic efficacy)
Adult: Initially, 1.5 mg/kg inj over 10-20 minutes, followed by of 0.2-0.5 mg/kg/hr infusion. CrCl (ml/min) Dosage Recommendation 30-60 Halve the usual dose. 10-30 Quarter the usual dose. <10 Not recommended. Special Populations: Renal impairment: CrCl 30-60 mL/min: ½ of the dose for both oral and IV route; 10-30 mL/min: ¼ of the dose for both oral and IV route.
Darob mite is used to treat arrhythmia -- a heart disease where the heartbeat is not regular or is too fast. When the heart is not pumping regularly or is pumping too fast, blood cannot be efficiently pumped out of the heart to other parts of the body. Darob mite slows down the heart rate and helps to make the heartbeat more regular.
Adult: PO Supraventricular and ventricular arrhythmias Initial: 80 mg/day in 1-2 divided doses, increase gradually every 2-3 days. Usual: 160-320 mg/day in 2 divided doses. Max: 640 mg/day. Life-threatening ventricular arrhythmias 480-640 mg/day. IV Acute arrhythmias 20-120 mg, may repeat 6 hrly if needed. For programmed electrical stimulation (to test antiarrhythmic efficacy) Initial: 1.5 mg/kg, then 0.2-0.5 mg/kg/hr infusion.